Nanobiotix Past Earnings Performance
Past criteria checks 0/6
Nanobiotix's earnings have been declining at an average annual rate of -1.1%, while the Biotechs industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 36.3% per year.
Key information
-1.11%
Earnings growth rate
9.55%
EPS growth rate
| Biotechs Industry Growth | 30.80% |
| Revenue growth rate | 36.30% |
| Return on equity | n/a |
| Net Margin | -73.52% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
NANO: CONVERGE Lung Cancer Efficacy Data Will Drive Future Repricing
Analysts have lifted the Nanobiotix fair value estimate from €47.80 to €52.20 after a sharp increase in the Street price target to €60, citing updated efficacy results from Part 1 of the Phase 2 CONVERGE study for JNJ-1900 in stage 3 inoperable non small cell lung cancer as key support. What’s in the News for Nanobiotix Nanobiotix completed a follow on equity offering of €85 million, including American Depositary Shares, ordinary shares and pre funded warrants, with per security prices in the €33.57 to €33.60 range and discounts of about €2 per security.
NANO: CONVERGE Data Will Drive Bullish Repricing Despite Execution Risks
The analyst price target for Nanobiotix has moved from €21.50 to €40.00, with analysts citing updated efficacy data from the Phase 2 CONVERGE study and recent target increases to around €60.00 as key drivers of their revised outlook. Analyst Commentary Recent research updates around Nanobiotix focus heavily on how the Phase 2 CONVERGE efficacy data may affect long term execution, growth prospects and valuation risk.NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Nanobiotix sees its analyst fair value estimate move from €29.24 to €47.80, with analysts pointing to recent upward revisions in price targets following updated CONVERGE study data as key support for the change. Analyst Commentary Recent research updates on Nanobiotix focus on the latest efficacy readouts from the Phase 2 CONVERGE study and how these data points feed into valuation frameworks and execution risk for the company.
NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Analysts have raised their fair value estimate for Nanobiotix from €45.00 to €60.00, citing recent price target increases and supportive efficacy data from updated Phase 2 CONVERGE study results. Analyst Commentary Recent Street research on Nanobiotix reflects a cluster of higher price targets following updated efficacy data from the Phase 2 CONVERGE study.Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential
Catalysts About Nanobiotix Nanobiotix develops nanoparticle based drug candidates intended to improve the effectiveness of existing cancer treatments such as radiotherapy and complex systemic therapies. What are the underlying business or industry changes driving this perspective?Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment
Catalysts About Nanobiotix Nanobiotix develops nanotechnology based therapies designed to work alongside existing cancer treatments such as radiotherapy. What are the underlying business or industry changes driving this perspective?Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech
Catalysts About Nanobiotix Nanobiotix is a biotechnology company focused on nanoscale therapies designed to work with existing treatments such as radiotherapy and complex biologic drugs. What are the underlying business or industry changes driving this perspective?New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)
Nanobiotix S.A. ( EPA:NANO ) shareholders will have a reason to smile today, with the analysts making substantial...Risks Still Elevated At These Prices As Nanobiotix S.A. (EPA:NANO) Shares Dive 27%
Nanobiotix S.A. ( EPA:NANO ) shareholders won't be pleased to see that the share price has had a very rough month...Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%
To the annoyance of some shareholders, Nanobiotix S.A. ( EPA:NANO ) shares are down a considerable 26% in the last...Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Nanobiotix S.A. ( EPA:NANO ) share price has fared very poorly over the last month, falling by a substantial 27...Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%
Nanobiotix S.A. ( EPA:NANO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is Nanobiotix (EPA:NANO) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Revenue & Expenses Breakdown
How Nanobiotix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 33 | -24 | 20 | 23 |
| 30 Sep 25 | 21 | -38 | 21 | 28 |
| 30 Jun 25 | 10 | -52 | 21 | 33 |
| 31 Mar 25 | 1 | -60 | 21 | 37 |
| 31 Dec 24 | -7 | -68 | 21 | 41 |
| 30 Sep 24 | 18 | -51 | 21 | 42 |
| 30 Jun 24 | 42 | -33 | 22 | 43 |
| 31 Mar 24 | 39 | -37 | 22 | 40 |
| 31 Dec 23 | 36 | -40 | 22 | 38 |
| 30 Sep 23 | 21 | -49 | 21 | 36 |
| 30 Jun 23 | 7 | -59 | 19 | 34 |
| 31 Mar 23 | 6 | -58 | 18 | 33 |
| 31 Dec 22 | 5 | -57 | 18 | 33 |
| 30 Sep 22 | 4 | -50 | 18 | 32 |
| 30 Jun 22 | 3 | -43 | 19 | 31 |
| 31 Mar 22 | 3 | -45 | 19 | 31 |
| 31 Dec 21 | 3 | -47 | 19 | 30 |
| 30 Sep 21 | 2 | -45 | 19 | 29 |
| 30 Jun 21 | 2 | -43 | 18 | 27 |
| 31 Mar 21 | 2 | -39 | 16 | 26 |
| 31 Dec 20 | 2 | -34 | 15 | 24 |
| 30 Sep 20 | 2 | -41 | 16 | 27 |
| 30 Jun 20 | 2 | -48 | 17 | 30 |
| 31 Mar 20 | 2 | -49 | 18 | 30 |
| 31 Dec 19 | 3 | -51 | 19 | 30 |
| 30 Sep 19 | 3 | -46 | 17 | 28 |
| 30 Jun 19 | 3 | -42 | 15 | 25 |
| 31 Mar 19 | 3 | -36 | 14 | 23 |
| 31 Dec 18 | 3 | -30 | 13 | 21 |
| 30 Sep 18 | 4 | -28 | 12 | 20 |
| 30 Jun 18 | 4 | -27 | 11 | 19 |
| 31 Mar 18 | 4 | -26 | 11 | 19 |
| 31 Dec 17 | 4 | -26 | 11 | 18 |
| 30 Sep 17 | 4 | -25 | 12 | 16 |
| 30 Jun 17 | 4 | -24 | 12 | 16 |
| 31 Mar 17 | 5 | -23 | 11 | 16 |
| 31 Dec 16 | 5 | -22 | 10 | 17 |
| 30 Sep 16 | 5 | -21 | 10 | 16 |
| 30 Jun 16 | 5 | -19 | 9 | 16 |
| 31 Mar 16 | 5 | -18 | 8 | 15 |
| 31 Dec 15 | 4 | -17 | 7 | 14 |
| 30 Sep 15 | 4 | -15 | 7 | 12 |
Quality Earnings: NANO is currently unprofitable.
Growing Profit Margin: NANO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NANO is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare NANO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NANO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.2%).
Return on Equity
High ROE: NANO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/14 17:54 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanobiotix S.A. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Philippa Gardner | Edison Investment Research |
| Jonathan Miller | Evercore ISI |
| Emmanuel Parot | Gilbert Dupont |